In a clinical research ecosystem that’s not known for its diversity, AI brings something meaningful to the table — but as powerful as smart tech is, it can also exacerbate the very equity problems it was made to solve.

AI-enabled data collection and management can be a game changer for life sciences companies in the drug development process.

Artificial intelligence (AI) is a transformative technology addressing critical global challenges, from predicting droughts to enhancing healthcare and mitigating climate change, while also boosting workplace productivity. Despite its potential, women remain significantly underrepresented in AI development, with only 26% of data and AI positions held by women. Closing this gender gap is crucial to fully harness AI's potential and innovation in various sectors.

The Diversity and Inclusion in UK Biotech report, published in March, offers a comprehensive examination of diversity, equity, and inclusion within the UK biotech sector. It highlights both positive aspects and challenges, providing valuable insights and recommendations for fostering a more diverse and inclusive industry.

Biotechnology, a sector with wide-ranging impacts, is addressing diversity and inclusion issues, particularly in leadership roles, as reports show underrepresentation of women and people of color in top positions. Embracing diversity is not only crucial for social equity but also essential for fostering innovation and better decision-making in a rapidly evolving industry.

Artificial intelligence (AI) is poised to revolutionize drug development in 2023, streamlining processes across the clinical trial spectrum, from patient recruitment and management to study build timelines. By leveraging AI, clinical trials can achieve faster, more efficient recruitment, reduce study build times from weeks to minutes, automate data management, and ultimately accelerate the delivery of life-saving drugs to market while enhancing the focus on drug discovery and improved patient treatments.

Emerging technologies are revolutionizing the field of clinical trials, making them more efficient and inclusive. Digital participants, including non-human entities like digital twins, powered by AI and advanced data science approaches, are helping streamline recruitment and enhance insights, while partnerships with organizations like CVS are expanding access to a wider and more diverse population, ultimately accelerating drug development and improving healthcare outcomes.

Article regarding diversity in AI in Psychotherapy

Artificial intelligence (AI)-enabled data collection and management can be a game changer for life sciences companies in the drug development process.